Zero Candida Announces Successful Listing on Frankfurt Stock Exchange and Details of Investor Webinar

VANCOUVER, BCJan. 16, 2025 /PRNewswire/ — Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the “Company” or “ZCT”), an Israeli FemTech medical device company focused on revolutionizing women’s health, is pleased to announce that its shares are now successfully listed on the Frankfurt Stock Exchange (FSE) under the trading symbol “9L2”. Their listing marks a significant milestone for the Company as it expands its global presence, now cross-listed on both the TSX Venture Exchange and the FSE, providing increased visibility and access to a broader pool of international investors.

Are you an angel?

Public Announcements

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ — Zero Candida Technologies,…

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Zero Candida Technologies, Inc. (TSXV: ZCT)(OTCQB: ZCTFF)(FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company focused on revolutionizing women’s health, is pleased to…

Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a Femtech company developing a SMART, AI-driven medical device to…